Breaking Down Lier Chemical Co.,LTD. Financial Health: Key Insights for Investors

Lier Chemical's latest results demand a closer look: a striking first-quarter net profit attributable to shareholders of 145-155 million yuan (a year‑on‑year surge of 203.08%-223.98%), first‑half operating revenue of 4.507 billion yuan (up 35.36% YoY) and trailing‑twelve‑months revenue of 8.83 billion yuan (up 25.59% YoY) against a 2024 full‑year revenue base of 7.31 billion; with a market capitalization near 10.46 billion yuan, EPS (TTM) of 0.58 yuan and a P/E of 22.14 the valuation signals tempered investor expectations while an EV of 13.86 billion and EV/EBITDA of 8.31 frame relative enterprise value; profitability metrics (ROE 6.33%, ROA 2.81%, net margin ~5.26%) sit alongside a conservative leverage profile (debt‑to‑equity 0.40), adequate liquidity (current ratio 1.30, quick ratio 0.86) and solid interest coverage (8.20), even as a high P/FCF of 62.64 invites scrutiny; add operational context - revenue per employee ≈ 1.53 million yuan across 5,760 staff - and you have a company balancing rapid recent profit rebound with exposure to raw material swings, regulatory and competitive risks and simultaneous growth levers from geographic expansion, new products, M&A and capacity investments that make this a must‑read for investors assessing upside versus risk.

Lier Chemical Co.,LTD. (002258.SZ) - Revenue Analysis

Lier Chemical Co.,LTD. (002258.SZ) has shown variable top-line performance across recent reporting periods, with strong recovery in 1H/TTM 2025 after a modest decline in 2024. Key reported figures and growth drivers are summarized below.

• Q1 2025 net profit attributable to shareholders: ~145-155 million yuan (YoY +203.08% to +223.98%), driven by higher sales volumes and higher realized prices of select products.
• 1H 2025 operating revenue: 4.507 billion yuan (YoY +35.36%).
• TTM revenue as of 2025-09-30: 8.83 billion yuan (YoY +25.59%).
• 2024 annual revenue: 7.31 billion yuan (YoY -6.87%).
• Revenue per employee: ~1.53 million yuan (total employees: 5,760).
• Market capitalization: ~10.46 billion yuan; P/S ratio: 1.18.

• Primary drivers of recent revenue improvement:
  • Volume recovery in core product lines.
  • Price gains for select specialty chemicals.
  • Operational leverage reflected in strong net profit growth in Q1 2025.
• Risks to monitor:
  • Commodity price volatility affecting raw material costs and margins.
  • Demand cyclicality in downstream industries.
  • Execution risk on capacity and cost controls as volumes scale.

For corporate mission and vision context, see: Mission Statement, Vision, & Core Values (2026) of Lier Chemical Co.,LTD.

Lier Chemical Co.,LTD. (002258.SZ) Profitability Metrics

• Q1 2025 net profit attributable to shareholders: guidance of ¥145.0-155.0 million, up 203.08%-223.98% YoY.
• H1 2025 net profit attributable to shareholders: guidance of ¥265.0-275.0 million, up 185.24%-196.00% YoY.
• TTM net income (as of 2025-09-30): ¥464.72 million.
• TTM EPS: ¥0.58 per share.

• Revenue mix and product pricing: recovery or improvement in margins likely contributed to the ~5.26% net margin and positive EPS trajectory.
• Cost structure and efficiency: improvements in gross-to-net conversion and operating leverage underpin rising net income and ROE of 6.33%.
• Scale and asset utilization: ROA at 2.81% indicates moderate asset efficiency relative to peers; incremental profit growth is improving asset returns.
• Volatility and sensitivity: guidance ranges indicate sensitivity to commodity/input costs, sales volume timing, and FX or one-off items.

Lier Chemical Co.,LTD. (002258.SZ) - Debt vs. Equity Structure

Key financial metrics show Lier Chemical Co.,LTD. (002258.SZ) maintains a moderate leverage profile with adequate short-term liquidity but some reliance on inventory for working capital. Relevant figures: debt-to-equity 0.40, current ratio 1.30, quick ratio 0.86, interest coverage 8.20, enterprise value (EV) 13.86 billion yuan, EV/EBITDA 8.31. Total liabilities and shareholders' equity are not specified in the available data.

• Debt-to-Equity (0.40): conservative-to-moderate leverage - 40 cents of debt per yuan of equity.
• Current Ratio (1.30): sufficient short-term liquidity to cover current liabilities with current assets.
• Quick Ratio (0.86): below 1.0, indicating potential short-term funding pressure if inventory cannot be converted quickly.
• Interest Coverage (8.20): robust ability to cover interest expense from operating earnings (EBIT ≈ 8.2× interest).
• EV and Valuation: EV = ¥13.86 billion with EV/EBITDA = 8.31, implying a moderate valuation relative to earnings before interest, taxes, depreciation, and amortization.

Practical considerations for investors:

• Operational resilience: interest coverage of 8.20 suggests earnings comfortably exceed interest obligations, lowering near-term solvency risk.
• Liquidity management: current ratio 1.30 is acceptable, but quick ratio 0.86 flags dependence on inventory turnover to meet immediate liabilities.
• Capital structure: debt-to-equity 0.40 provides room for additional financing if needed without excessive leverage strain.
• Valuation context: EV/EBITDA 8.31 positions the company at a moderate earnings multiple - compare with peers for relative attractiveness.

For more on ownership, trading behavior, and investor mix that contextualize these metrics, see: Exploring Lier Chemical Co.,LTD. Investor Profile: Who's Buying and Why?

Lier Chemical Co.,LTD. (002258.SZ) - Liquidity and Solvency

Lier Chemical Co.,LTD.'s recent liquidity and solvency metrics indicate a generally stable financial position with some short-term liquidity nuances that investors should note.

• Current ratio: 1.30 - sufficient short-term assets to cover current liabilities, offering a modest buffer.
• Quick ratio: 0.86 - below 1.0, suggesting reliance on inventory conversion to meet immediate obligations.
• Interest coverage ratio: 8.20 - strong ability to cover interest expenses from operating earnings.
• Debt-to-equity ratio: 0.40 - moderate leverage, implying balanced use of debt versus equity financing.

Key investor considerations:

• Short-term liquidity: Quick ratio < 1.0 means monitor inventory turnover and receivables conversion times.
• Interest risk: Interest coverage of 8.20 provides ample cushion against rising rates or margin compression.
• Leverage profile: Debt-to-equity at 0.40 allows capacity for incremental borrowing if needed without overly stretching balance sheet risk.
• Data gaps: Absence of specified total assets and liabilities limits deeper solvency stress-testing; seek full balance sheet disclosure for scenario analysis.

Additional context and investor-focused details can be found here: Exploring Lier Chemical Co.,LTD. Investor Profile: Who's Buying and Why?

Lier Chemical Co.,LTD. (002258.SZ) - Valuation Analysis

• Market capitalization: 10.46 billion yuan
• P/S ratio: 1.18
• TTM EPS: 0.58 yuan; trailing P/E: 22.14
• Forward P/E: 21.97
• Enterprise Value (EV): 13.86 billion yuan; EV/EBITDA: 8.31
• P/B ratio: 1.11
• P/FCF ratio: 62.64

• Trailing and forward P/E near 22 imply the market prices in steady earnings rather than rapid expansion.
• EV/EBITDA of 8.31 indicates a moderate enterprise-level valuation versus peers in chemical manufacturing.
• P/FCF at 62.64 signals either constrained free cash flow or an elevated price relative to cash generation, warranting scrutiny of cash conversion and capex timing.
• P/B of 1.11 suggests limited margin of safety relative to net assets but not a deep premium.

Lier Chemical Co.,LTD. (002258.SZ) Risk Factors

• Raw material price volatility - glyphosate and other inputs

• Competitive intensity - domestic and international peers

• Regulatory shifts in the chemical industry

• Foreign exchange exposure

• Macroeconomic demand cycles

• Environmental and compliance cost escalation

• Mitigants and indicators to monitor
• Hedging policies for FX and key commodity inputs
• Capital expenditure guidance and environmental CAPEX disclosure
• Customer concentration ratios and contract duration
• Regulatory permit status and compliance audit outcomes

Lier Chemical Co.,LTD. (002258.SZ) - Growth Opportunities

Lier Chemical Co.,LTD. (002258.SZ) is positioned to capitalize on several strategic growth levers that can materially improve topline resilience and margin profile over the next 3-5 years. Below are prioritized growth opportunities with quantified targets and operational levers.

• Geographic expansion into Latin America (Brazil, Argentina) to capture specialty-chemical demand growth tied to agriculture and industrial coatings.
• New product development and portfolio diversification to move up the value chain and reduce cyclicality from commodity segments.
• Strategic acquisitions to strengthen market share, broaden product lines and gain manufacturing synergies - e.g., the proposed Shandong Huimeng Biotechnology Co., Ltd. acquisition.
• Increased R&D investment and process innovation to lower unit costs and introduce higher-margin formulations.
• Growth of online sales channels (B2B e-commerce and distributor platforms) to shorten sales cycles and expand reach.
• Capacity expansion via new or upgraded facilities to meet rising demand and improve lead times.

Expansion into Brazil and Argentina offers exposure to large end markets for agrochemicals, adhesives and specialty intermediates. Typical addressable market sizes and near-term targets could look like:

• Brazil: target initial sales RMB 150-250 million within 24 months post-entry; long-term TAM in specialty chemical segments > RMB 80 billion.
• Argentina: target initial sales RMB 50-120 million within 24 months; complementary logistics hub potential for MERCOSUR distribution.

Product development and diversification: prioritizing higher-margin specialty intermediates, functional additives and bio-based chemistries - with an internal goal to introduce 6-10 new SKU families over three years. Expected financial impact:

Strategic M&A (e.g., Shandong Huimeng Biotechnology Co., Ltd.) can deliver:

• Immediate revenue accretion: estimated addition of RMB 200-400 million depending on deal size.
• Cost synergies: 3-6% of combined COGS from procurement and plant rationalization.
• Enhanced R&D/tech capabilities and faster route-to-market for biologically derived intermediates.

R&D and innovation investments should scale from ~3% to 4-5% of revenue to support new product pipelines and process efficiency. Key R&D KPIs to monitor:

• Number of patents filed per year: target 8-15
• Time-to-market for new formulations: target 12-18 months
• Yield/process cost improvements: target 5-10% reduction in variable production costs over 3 years

Online sales and channel strategy: prioritize a hybrid B2B e-commerce approach and distributor partnerships to reach a broader customer base. Targets:

• Double online contribution to 10-15% of revenue within 3 years
• Increase repeat B2B digital customers by 30-50%
• Reduce sales cycle by ~20% for digitally-enabled transactions

Production capacity enhancements: planned capex should focus on:

• Adding 20-40% capacity in specialty product lines where demand is growing
• Improving logistic throughput with regional warehouses in Latin America
• Adopting modular plant designs to accelerate ramp-up (6-12 months)

Key execution risks to monitor include commodity feedstock volatility (affecting margins), integration risks for acquisitions, regulatory/registration timelines in overseas markets, and potential FX exposure when operating in BRL/ARS. Investors should track quarterly sales by region, R&D spend, gross-margin trends, and any updates on the Shandong Huimeng transaction.

For alignment with corporate purpose and strategic pillars, see Mission Statement, Vision, & Core Values (2026) of Lier Chemical Co.,LTD.